Company Spotlight: iRhythm ZEUS Platform - The AI ECG Clearance With No New Clinical Trials

We unpack the FDA 510(k) summary for iRhythm's ZEUS Platform, a software system that uses deep learning to process and analyze ECG data from wearable cardiac monitors. We discuss how it achieved FDA clearance based on substantial equivalence to a predicate device, relying on engineering standards and risk management testing rather than new clinical trials.

Key points

• The ZEUS Platform is cleared as a Class II Programmable Diagnostic Computer to process and analyze ECGs for adults.
• It utilizes artificial intelligence-based deep learning (ECGDLv2 and ECGDLv3) to identify a wide range of beats and rhythms, including AFib and pauses >3 seconds.
• The software acts as an automated triage tool; reports are reviewed by Qualified Cardiac Technicians (QCTs) before final interpretation by a clinician.
• The device is not intended for hemodynamically unstable patients or those requiring immediate emergency intervention.
• Because clearance was obtained via the 510(k) pathway (substantial equivalence), the FDA summary contains no new clinical testing data or specific accuracy metrics.

Source: FDA 510(k) summary K252859: ZEUS Platform (FG0501US) (iRhythm Technologies) - U.S. Food and Drug Administration, 2026

This episode is an AI-generated conversation summarising a public document; the hosts' voices are synthetic. It is for information only and is not medical advice. Always refer to the original source.

Company: iRhythm Technologies (irhythmtech.com) · Product: ZEUS Platform (FG0501US) · FDA 510(k) K252859

Full transcript: https://ai-in-medicine-podcast.vercel.app/episodes/company-spotlight-irhythm-zeus-platform-the-ai-ecg-clearance-with-no-n-ed856a